

Contents

Welcome Message	iii
EULAR 2014 Abstracts Reviewers	iv

Speakers Abstracts

Speaker Presentations

Wednesday, 11 June 2014

SP0001	Welcome session for all health care professional attendees	2
SP0002–SP0004	Giant cell arteritis: new perspectives	2
SP0005–SP0007	Markers of osteoarthritis: what has it brought and what will it bring us	3
SP0008	HOT session 1: Comorbidity in rheumatic diseases / Systemic lupus erythematosus	3
SP0009–SP0010	Chronic periaortitis and IgG4 related diseases	4
SP0011	Adaptive immunity	4
SP0012–SP0013	Gout. Why crystals inflame, where they are located and how they may form	5
SP0014–SP0015	Health professionals and ultrasound - how to implement imaging into clinical practice	5
SP0016	Basic epidemiology explained	5
SP0017	EULAR projects in investigative rheumatology	5
SP0018–SP0019	MRI basic I	6
SP0020–SP0021	Ultrasound basic I	6
SP0022–SP0025	Food as therapy - supporting healthy choices	6
SP0026–SP0027	Biosimilars: a SWOT analysis	7
SP0028–SP0029	Managing neck and shoulder pain	8
SP0030	HOT session 2: Sjögren's syndrome / Myositis	8
SP0031–SP0033	Biomarkers: the future or a waste of resources?	9
SP0034–SP0035	Raynaud's phenomenon and rheumatic diseases: primary versus secondary	9
SP0036–SP0038	PMR - establishing therapeutic order at last	10
SP0039–SP0040	Circadian rhythms and chronomodulation of the immune/inflammatory response	11
SP0041–SP0042	Spondyloarthritis: revisiting gut, enthesitis and HLA-B27 in the IL23 era	11
SP0043–SP0044	Promoting a healthy lifestyle among patients with arthritis - how are health professionals doing? ..	12
SP0045–SP0046	Basic immunology explained	13
SP0047–SP0048	Educational activities within EULAR ESCET (EULAR Standing Committee for Education and Training)	13
SP0049–SP0050	Political campaigning	14

Thursday, 12 June 2014

SP0051–SP0053	Lipid mediators and inflammation	14
SP0054	Stem cells and inflammation	15
SP0055	WIN session 2: Pain and fibromyalgia / Physical therapy	15
SP0056	HOT session 3: Vasculitis / Raynaud's phenomenon and systemic sclerosis	15
SP0057–SP0058	I-Patient - the role of smart decision making	16
SP0059	WIN session 3: Early arthritis / Myositis	16
SP0060–SP0061	Analgesics for rheumatic diseases: re-thinking old drugs	16
SP0062–SP0064	Imaging biomarkers in arthritis. Are MRI/US useful tools?	17
SP0065–SP0066	What is the target in RA	18
SP0067–SP0069	Development and implementation of outcome measures	18
SP0070–SP0071	Anti-TNF treatment. How do we stand regarding tuberculosis and cancer	19
SP0072	Autoinflammatory diseases	20
SP0073–SP0074	Joint development - a magic toolbox for the rheumatologist	20
SP0075–SP0076	Proteasome	21
SP0077–SP0080	Targets and mechanisms of treatment in chronic pain	21

SP0081	Career development	22
SP0082–SP0083	Ultrasound advanced I	22
SP0084–SP0086	Don't let the economic crisis go to waste	23
SP0087–SP0088	WIN session 4: SLE and APS / Vasculitis	23
SP0089–SP0090	Similarities and differences between RA treatment guidelines among different regions in the world and the reason for this	24
SP0091	Changing concepts of gout	24
SP0092–SP0093	HOT session 4: Osteoporosis / Management of pain	25
SP0094–SP0097	Patient's perspectives in rheumatologic outcomes	25
SP0098–SP0100	Sjögren syndrome: lessons for new targets and new clinical trials	26
SP0101–SP0103	The global burden of disease project - implications for clinical practice and decision makers	27
SP0104–SP0105	Immune inhibition	27
SP0106–SP0108	eHealth literacy on rheumatic diseases - analysing the power of the internet	28
SP0109	eHealth	29
SP0110–SP0111	European initiatives in paediatric rheumatology	29
SP0112–SP0116	Capillaroscopy I	30
SP0117–SP0118	Ultrasound basic II	31
SP0119	What's new: latest advances in treatment and management of RMD	32
Friday, 13 June 2014		
SP0120	EULAR-EFIS session: Innate lymphoid cells ILC's in health and disease	32
SP0121–SP0123	Joint homeostasis in OA	32
SP0124	WIN session 5: Clinical implications of imaging advances / Osteoporosis and bone diseases	34
SP0125–SP0126	HOT session 5: Fibromyalgia / Spondyloarthritis/ankylosing spondylitis	34
SP0127–SP0128	Therapeutic drug monitoring	35
SP0129–SP0130	HOT session 6: Localised rheumatic syndromes / Osteoarthritis	35
SP0131–SP0132	Glucocorticoids as confounders	36
SP0133–SP0134	Future hot topics	36
SP0135–SP0136	Preclinical models of rheumatic disease. What do they teach us?	37
SP0137	Long-non coding RNAs/epigenetics	37
SP0138–SP0141	Is it a flare? Focus on patient self-reported disease activity measures in RA	37
SP0142–SP0144	EULAR projects in musculoskeletal imaging	38
SP0145	MRI basic II	39
SP0146	Improving your graphs and tables for publication and presentation I	39
SP0147–SP0150	Healthy ageing I - growing up with an RMD	39
SP0151	WIN session 7: Infections and rheumatic diseases / Comorbidity in rheumatic diseases	40
SP0152–SP0153	Clinical use of glucocorticoid	41
SP0154	Axial spondyloarthritis: new name of an old disease	41
SP0155	HOT session 7: Gout treatment and a touch on CPPD treatment / Imaging in diagnosis and management	41
SP0156–SP0158	Improving access to rheumatologist for patients with inflammatory arthritis	42
SP0159–SP0160	Innate regulation of inflammation	42
SP0161–SP0162	Novel auto-antibodies	43
SP0163–SP0164	Organ manifestations in scleroderma	43
SP0165–SP0167	Practical implementation of annual reviews in patients with inflammatory arthritis - sharing experiences	44
SP0168	How to get involved and how to influence the work of Eular health professionals	45
SP0169	MRI advanced I	45
SP0170–SP0173	Capillaroscopy II	45
SP0174–SP0177	Healthy ageing II - growing older with an RMD	47
Saturday, 14 June 2014		
SP0178	WIN session 8: Sjögren's syndrome / Gout and crystal diseases	47
SP0179–SP0180	Early systemic sclerosis	48
SP0181–SP0183	Osteoimmunology, from bench to bedside. How to interpret new findings	48
SP0184–SP0185	HOT session 8: Juvenile idiopathic arthritis JIA and other paediatric diseases / Psoriatic arthritis	49
SP0186–SP0188	Optimal usage of longitudinal databases	49

SP0189	Therapy of refractory autoimmune diseases	50
SP0190	Rheumatic diseases in children	50
SP0191	Dendritic cell biology for clinicians, role in vaccination?	50
SP0192–SP0193	Cellular energy metabolism, immunity and rheumatic diseases	50
SP0194–SP0196	The scleroderma patient-centered intervention network (SPIN): meeting the challenges of research into a rare disease	51
SP0197	Improving your graphs and tables for publication and presentation II	51
SP0198–SP0199	Facilitating a normal life - easy travelling for people with RMDs	51
SP0200	WIN session 9: Psoriatic arthritis/Osteoarthritis	52
SP0201–SP0203	Modern imaging techniques in osteoporosis	52
SP0204–SP0205	HOT session 9: Treatment of undifferentiated/early arthritis/IgG4 associated diseases	53
SP0206–SP0207	From the general to the particular	53
SP0208–SP0210	Advanced imaging applied in clinical trials	53
SP0211–SP0212	Role of hypoxia in rheumatic disease	54
SP0213	Sterile inflammation	55
SP0214–SP0217	Patient education for people with inflammatory rheumatic disease	55
SP0218	Marketing rheumatology: spreading the gospel	56
SP0219–SP0220	Peer support in chronic diseases	56

Scientific Abstracts

Oral Presentations

Wednesday, 11 June 2014

OP0001–OP0002	Giant cell arteritis: new perspectives	60
OP0003	Markers of osteoarthritis: what has it brought and what will it bring us	60
OP0004–OP0005-HPR	Adherence: the new challenge for rheumatology	61
OP0006–OP0007	Juvenile idiopathic arthritis	61
OP0008	Gout. Why crystals inflame, where they are located and how they may form	62
OP0009-HPR	Health professionals and ultrasound - how to implement imaging into clinical practice	63
OP0010-HPR	Food as therapy - supporting healthy choices	63
OP0011–OP0012	Biosimilars: a SWOT analysis	63
OP0013–OP0014	Managing neck and shoulder pain	64
OP0015–OP0016	Biomarkers: the future or a waste of resources?	65
OP0017–OP0018	Spondyloarthritis: revisiting gut, entheses and HLA-B27 in the IL23 era	66
OP0019-HPR–OP0020-HPR	Promoting a healthy lifestyle among patients with arthritis - how are health professionals doing?	67
OP0021-PARE–OP0022-PARE	Political campaigning	67

Thursday, 12 June 2014

OP0023	Lipid mediators and inflammation	68
OP0024–OP0025	Stem cells and inflammation	68
OP0026–OP0032	Abstract session: Novel non-TNF biologics treatment of RA	69
OP0033–OP0040	Abstract session: Rheumatoid arthritis: predictors, prognosis and outcome	72
OP0041–OP0048	Abstract session: SLE, Sjögren's syndrome - treatment	75
OP0049–OP0056	Abstract session: New insights into imaging arthritis	79
OP0057–OP0064	Abstract session: Osteoarthritis clinical aspects	82
OP0065–OP0072	Abstract session: What is new with anti-TNF's in RA	85
OP0073–OP0080	Abstract session: Genes, disease activity and treatment of psoriatic arthritis	88
OP0081-HPR–OP0088-HPR	Abstract session: Evaluating practice	92
OP0089–OP0096	Abstract session: Scleroderma/myositis: clinical aspects, prognostic biomarkers, outcome measures	95
OP0097–OP0104	Abstract session: Lupus pathogenesis unraveling	98
OP0105–OP0112	Abstract session: Cytokines and inflammatory mediators	100
OP0113–OP0120	Abstract session: Orphan diseases - what is new?	103
OP0121-PARE	I-Patient - the role of smart decision making	106
OP0122	Analgesics for rheumatic diseases: re-thinking old drugs	107
OP0123–OP0124	Imaging biomarkers in arthritis. Are MRI/US useful tools?	107

OP0125	What is the target in RA	108
OP0126–OP0127	Development and implementation of outcome measures	108
OP0128	Autoinflammatory diseases	109
OP0129–OP0130	Joint development - a magic toolbox for the rheumatologist	109
OP0131	Proteasome	110
OP0132-HPR	Targets and mechanisms of treatment in chronic pain	110
OP0133	Career development	111
OP0134-PARE	Don't let the economic crisis go to waste	111
OP0135–OP0136	Changing concepts of gout	111
OP0137-HPR	Patient's perspectives in rheumatologic outcomes	112
OP0138–OP0139	Immune inhibition	112
OP0140-HPR	eHealth literacy on rheumatic diseases - analysing the power of the internet	113
OP0141	eHealth	114
OP0142–OP0143	European initiatives in paediatric rheumatology	114
Friday, 13 June 2014		
OP0144–OP0146	Joint homeostasis in OA	115
OP0147–OP0154	Abstract session: RA - non biologic and small molecules	116
OP0155–OP0162	Abstract session: Treatment of spondyloarthritis: moving forward	120
OP0163–OP0170	Abstract session: Comorbidity and disease impact in RA	123
OP0171–OP0178	Abstract session: The biology of rheumatoid arthritis	127
OP0179–OP0186	Abstract session: Paediatric rheumatology/PReS	130
OP0187–OP0194	Abstract session: Emerging concepts in genomics and genetics	133
OP0195–OP0202	Abstract session: Epidemiology, outcomes and health services research	136
OP0203-HPR–OP0210-HPR	Abstract session: Tracking the journey	139
OP0211–OP0218	Abstract session: SLE, Sjögren's and APS - clinical aspects (other than treatment)	142
OP0219–OP0226	Abstract session: Innate and adaptive immune system in rheumatic diseases	145
OP0227–OP0234	Abstract session: Vasculitis	148
OP0235–OP0242	Abstract session: Translational science in systemic sclerosis and myositis	151
OP0243-PARE–OP0249-PARE	Abstract session: PARE	154
OP0250–OP0251	Getting to the heart of connective tissue diseases	156
OP0252–OP0253	Therapeutic drug monitoring	157
OP0254–OP0255	Glucocorticoids as confounders	157
OP0256–OP0257	Long-non coding RNAs/epigenetics	158
OP0258-HPR	Is it a flare? Focus on patient self-reported disease activity measures in RA	159
OP0259-PARE	Healthy ageing I - growing up with an RMD	159
OP0260–OP0261	Clinical use of glucocorticoid	160
OP0262–OP0263	Axial spondyloarthritis: new name of an old disease	160
OP0264	Innate regulation of inflammation	161
OP0265–OP0266	Novel auto-antibodies	161
OP0267–OP0268	Organ manifestations in scleroderma	162
OP0269-HPR–OP0270-HPR	Practical implementation of annual reviews in patients with inflammatory arthritis – sharing experiences	163
OP0271–OP0272	What we have learnt - from exchange visits and educational research projects	164
OP0273-PARE	Healthy ageing II - growing older with an RMD	165
Saturday, 14 June 2014		
OP0274–OP0275	Early systemic sclerosis	165
OP0276–OP0277	Osteoimmunology, from bench to bedside. How to interpret new findings	166
OP0278–OP0279	Optimal usage of longitudinal databases	167
OP0280–OP0281	Rheumatic diseases in children	168
OP0282–OP0283	Dendritic cell biology for clinicians, role in vaccination?	168
OP0284–OP0285	Cellular energy metabolism, immunity and rheumatic diseases	169
OP0286-HPR–OP0287-HPR	The scleroderma patient-centered intervention network (SPIN): meeting the challenges of research into a rare disease	170
OP0288-PARE	Facilitating a normal life - easy travelling for people with RMDs	170
OP0289–OP0290	Update on classification and management of myositis	171
OP0291–OP0292	Modern imaging techniques in osteoporosis	172

OP0293–OP0294	From the general to the particular	172
OP0295–OP0296	Role of hypoxia in rheumatic disease	174
OP0297–OP0298	Sterile inflammation	174
OP0299-HPR	Patient education for people with inflammatory rheumatic disease	175
OP0300-PARE–OP0301-PARE	Peer support in chronic diseases	175

Late Breaking Abstract

Thursday, 12 June 2014

LB0001	Abstract session: Novel non-TNF biologics treatment of RA	176
--------	---	-----

Poster Presentations

Thursday, 12 June 2014

Guided Poster Tours

T1: Clinical aspects and management of psoriatic arthritis (SAT0408, SAT0413, SAT0384, SAT0411, SAT0403, SAT0385, SAT0387, SAT0400, SAT0386, SAT0381)	
T2: Emerging concepts in genomics and genetics (THU0460, THU0482, THU0454, THU0456, THU0468, THU0488, THU0480, THU0475, THU0491, THU0477)	
T3: Infection-related rheumatic disease (THU0282, THU0299, THU0290, THU0289, THU0296, THU0295, THU0283, THU0300, THU0281, THU0287)	
T4: Scleroderma and myositis - clinical aspects (FRI0481, FRI0484, FRI0480, FRI0479, FRI0482, FRI0494, FRI0497, FRI0485, FRI0505, FRI0478)	
T5: PreS (FRI0528, FRI0531, FRI0556, FRI0550, FRI0554, FRI0547, FRI0544, FRI0560, FRI0553)	
T6: SLE, Sjögren's and APS: etiology, pathogenesis and animal models (THU0040, THU0047, THU0043, THU0054, THU0048, THU0055, THU0053, THU0051, THU0057, THU0042)	
T8: Osteoarthritis - treatment and markers (SAT0450, SAT0427, SAT0415, SAT0447, SAT0448, SAT0419, SAT0417, SAT0418, SAT0425)	
T9: Managing RA and beyond (FRI0093, FRI0090, FRI0055, FRI0054, FRI0095, FRI0099, FRI0075, FRI0073)	
T10: Spondyloarthritis - clinical aspects (FRI0119, FRI0155, FRI0154, FRI0139, FRI0115, FRI0147, FRI0114, FRI0111, FRI0112, FRI0150)	
T11: RA: prediction of outcome (SAT0042, SAT0043, SAT0050, SAT0063, SAT0040, SAT0035, SAT0047, SAT0036, SAT0054, SAT0038)	

Posters

THU0001–THU0037	SLE, Sjögren's and APS - clinical aspects (other than treatment)	177
THU0038–THU0059	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	189
THU0060–THU0108	Spondyloarthritis - clinical aspects (other than treatment)	197
THU0109–THU0150	Rheumatoid arthritis - non biologic treatment and small molecules	215
THU0151–THU0191	Rheumatoid arthritis - anti-TNF therapy	231
THU0192–THU0224	Osteoarthritis	248
THU0225–THU0279	Rheumatoid arthritis - prognosis, predictors and outcome	259
THU0280–THU0304	Infection-related rheumatic diseases	280
THU0305–THU0330	Fibromyalgia and pain in rheumatic diseases	288
THU0331–THU0359	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	296
THU0360–THU0409	Other orphan diseases	307
THU0410–THU0453	Epidemiology, health services and outcome research	323
THU0454–THU0494	Genomics, genetics and epigenetics of rheumatic diseases	340
THU0495–THU0510	Adaptative immunity (T cells and B cells) in rheumatic diseases	354
THU0511–THU0519	Innate immunity in rheumatic diseases	360
THU0520–THU0555	Cytokines and inflammatory mediators	363
THU0556–THU0571	Rehabilitation	375

Friday, 13 June 2014**Guided Poster Tours**

- F1: RA - non biologic and small molecules
(THU0141, THU0140, THU0121, THU0126, THU0115, THU0150, THU0134, THU0132, THU0114, THU0122)
- F2: Epidemiology, health services research
(THU0448, THU0453, THU0451, THU0412, THU0449, THU0424, THU0423, THU0433, THU0450)
- F4: RA: Prognosis of outcome
(SAT0044, SAT0053, SAT0041, SAT0052, SAT0059, SAT0056, SAT0055, SAT0051, SAT0073, SAT0049, SAT0058)
- F6: Innate and adaptive immunity in rheumatic diseases
(THU0514, THU0511, THU0516, THU0515, THU0519, THU0495, THU0503, THU0500, THU0507, THU0498)
- F7: Crystal arthritis
(SAT0503, SAT0510, SAT0516, SAT0502, SAT0535, SAT0545, SAT0505)
- F8: Orphan diseases
(THU0391, THU0382, THU0376, THU0365, THU0362, THU0396, THU0395, THU0392, THU0377, THU0373)
- F9: A walk in the treatment forest of SpA
(SAT0364, SAT0373, SAT0344, SAT0351, SAT0357, SAT0376, SAT0358, SAT0332, SAT0331, SAT0371)
- F10: The biology of rheumatoid arthritis
(FRI0363, FRI0350, FRI0362, FRI0365, FRI0357, FRI0337, FRI0356, FRI0346, FRI0354)
- F11: SLE, Sjögren's and APS - clinical aspects (other than treatment)
(THU0013, THU0023, THU0011, THU0008, THU0012, THU0014, THU0005, THU0001, THU0002)

Posters

FRI0001–FRI0047	Rheumatoid arthritis - prognosis, predictors and outcome	381
FRI0048–FRI0108	Rheumatoid arthritis - comorbidity and clinical aspects	398
FRI0109–FRI0158	Spondyloarthritis - clinical aspects (other than treatment)	421
FRI0159–FRI0169	Spondyloarthritis - etiology, pathogenesis and animal models	439
FRI0170–FRI0224	Epidemiology, health services and outcome research	443
FRI0225–FRI0250	Diagnostics and imaging procedures	464
FRI0251–FRI0292	Rheumatoid arthritis - anti-TNF therapy	474
FRI0293–FRI0336	Rheumatoid arthritis - other biologic treatment	490
FRI0337–FRI0370	Rheumatoid arthritis - etiology, pathogenesis and animal models	509
FRI0371–FRI0396	SLE, Sjögren's and APS - treatment	521
FRI0397–FRI0440	SLE, Sjögren's and APS - clinical aspects (other than treatment)	531
FRI0442–FRI0477	Vasculitis	547
FRI0478–FRI0511	Scleroderma, myositis and related syndromes - clinical aspects and treatment	560
FRI0512–FRI0525	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	573
FRI0526–FRI0527	Basic science in paediatric rheumatology	577
FRI0528–FRI0560	Paediatric rheumatology	578

Saturday, 14 June 2014**Guided Poster Tours**

- S1: Inside and outside the joint. What's new in imaging?
(FRI0249, FRI0246, FRI0226, FRI0227, FRI0225, FRI0247, FRI0231, FRI0239, FRI0248, FRI0250)
- S3: Treatment options in SLE, what is new?
(FRI0374, FRI0387, FRI0373, FRI0394, FRI0386, FRI0375, FRI0382, FRI0392, FRI0384, FRI0396)
- S4: Vasculitis
(FRI0455, FRI0461, FRI0474, FRI0463, FRI0473, FRI0460, FRI0476, FRI0477, FRI0456)
- S5: Education in clinical rheumatology
(SAT0584, SAT0575, SAT0581, SAT0577, SAT0587, SAT0588)
- S6: Fibromyalgia and back pain
(THU0329, THU0320, THU0328, SAT0579, THU0322, THU0330, THU0305, THU0314, THU0309, THU0341)
- S7: RA anti-TNF
(FRI0252, FRI0288, FRI0254, FRI0287, FRI0258, FRI0255, FRI0251, THU0159, THU0157)
- S8: Rehabilitation
(THU0571, THU0565, THU0562, THU0564, THU0560, THU0567, THU0570, THU0563, THU0568, THU0569)
- S9: Osteoporosis
(SAT0463, SAT0479, SAT0484, SAT0499, SAT0490, SAT0480, SAT0496, SAT0471, SAT0460, SAT0475)

S10: Pathophysiology of scleroderma and myositis (FRI0520, FRI0521, FRI0513, FRI0514, FRI0518, FRI0517, FRI0525, FRI0519, FRI0515, FRI0512)	
S11: SpA updates on pathogenesis (FRI0163, FRI0166, FRI0169, FRI0165, FRI0161, FRI0164, FRI0162, FRI0159, FRI0168, FRI0167)	

Posters

SAT0001–SAT0034	SLE, Sjögren's and APS - clinical aspects (other than treatment)	590
SAT0035–SAT0074	Rheumatoid arthritis - prognosis, predictors and outcome	601
SAT0075–SAT0108	Epidemiology, health services and outcome research	617
SAT0109–SAT0164	Rheumatoid arthritis - comorbidity and clinical aspects	630
SAT0165–SAT0224	Diagnostics and imaging procedures	650
SAT0225–SAT0264	Rheumatoid arthritis - other biologic treatment	671
SAT0265–SAT0295	Vasculitis	689
SAT0296–SAT0330	Scleroderma, myositis and related syndromes - clinical aspects and treatment	700
SAT0331–SAT0376	Spondyloarthritis - treatment	711
SAT0377–SAT0414	Psoriatic arthritis	730
SAT0415–SAT0455	Osteoarthritis	745
SAT0456–SAT0499	Osteoporosis	758
SAT0500–SAT0545	Bone diseases other than osteoporosis, metabolic diseases and crystal diseases	773
SAT0546–SAT0574	Cartilage, synovium and osteoimmunology	788
SAT0575–SAT0588	Education	798

Abstracts Accepted for Publication

AB0001–AB0020	Genomics, genetics and epigenetics of rheumatic diseases	804
AB0021–AB0039	Adaptative immunity (T cells and B cells) in rheumatic diseases	810
AB0040–AB0053	Innate immunity in rheumatic diseases	817
AB0054–AB0091	Cytokines and inflammatory mediators	821
AB0092–AB0104	Cartilage, synovium and osteoimmunology	834
AB0105–AB0157	Rheumatoid arthritis - etiology, pathogenesis and animal models	838
AB0158–AB0168	Spondyloarthritis - etiology, pathogenesis and animal models	855
AB0169–AB0192	SLE, Sjögren's and APS - etiology, pathogenesis and animal models	859
AB0193–AB0215	Scleroderma, myositis and related syndromes - etiology, pathogenesis and animal models	867
AB0216–AB0217	Basic science in paediatric rheumatology	875
AB0218–AB0299	Rheumatoid arthritis - prognosis, predictors and outcome	875
AB0300–AB0369	Rheumatoid arthritis - comorbidity and clinical aspects	903
AB0370–AB0417	Rheumatoid arthritis - anti-TNF therapy	927
AB0418–AB0453	Rheumatoid arthritis - other biologic treatment	945
AB0454–AB0478	Rheumatoid arthritis - non biologic treatment and small molecules	958
AB0480–AB0501	SLE, Sjögren's and APS - treatment	966
AB0502–AB0562	SLE, Sjögren's and APS - clinical aspects (other than treatment)	973
AB0563–AB0605	Vasculitis	992
AB0606–AB0652	Scleroderma, myositis and related syndromes - clinical aspects and treatment	1006
AB0653–AB0676	Spondyloarthritis - treatment	1021
AB0677–AB0737	Spondyloarthritis - clinical aspects (other than treatment)	1029
AB0738–AB0766	Psoriatic arthritis	1047
AB0767–AB0801	Osteoarthritis	1058
AB0802–AB0825	Osteoporosis	1069
AB0826–AB0849	Bone diseases other than osteoporosis, metabolic diseases and crystal diseases	1076
AB0850–AB0855	Infection-related rheumatic diseases	1084
AB0856–AB0864	Fibromyalgia and pain in rheumatic diseases	1085
AB0865–AB0879	Back pain, mechanical musculoskeletal problems, local soft tissue disorders	1088
AB0880–AB0917	Paediatric rheumatology	1092
AB0918–AB0940	Other orphan diseases	1103
AB0941–AB1027	Diagnostics and imaging procedures	1111
AB1028–AB1119	Epidemiology, health services and outcome research	1140
AB1120–AB1126	Rehabilitation	1172
AB1127–AB1136	Education	1175

Health Professionals in Rheumatology Abstracts

Oral Presentations

Wednesday, 11 June 2014

OP0005-HPR	Adherence: the new challenge for rheumatology	1180
OP0009-HPR	Health professionals and ultrasound - how to implement imaging into clinical practice	1180
OP0010-HPR	Food as therapy - supporting healthy choices	1180
OP0019-HPR–OP0020-HPR	Promoting a healthy lifestyle among patients with arthritis - how are health professionals doing?	1181

Thursday, 12 June 2014

OP0081-HPR–OP0088-HPR	Abstract session: Evaluating practice	1182
OP0132-HPR	Targets and mechanisms of treatment in chronic pain	1184
OP0137-HPR	Patient's perspectives in rheumatologic outcomes	1185
OP0140-HPR	eHealth literacy on rheumatic diseases - analysing the power of the internet	1185

Friday, 13 June 2014

OP0203-HPR–OP0210-HPR	Abstract session: Tracking the journey	1185
OP0258-HPR	Is it a flare? Focus on patient self-reported disease activity measures in RA	1188
OP0269-HPR–OP0270-HPR	Practical implementation of annual reviews in patients with inflammatory arthritis – sharing experiences	1189

Saturday, 14 June 2014

OP0286-HPR–OP0287-HPR	The scleroderma patient-centered intervention network (SPIN): meeting the challenges of research into a rare disease	1189
OP0299-HPR	Patient education for people with inflammatory rheumatic disease	1190

Poster Presentations

Thursday, 12 June 2014

Posters

THU0572-HPR–THU0587-HPR	Nursing	1191
THU0588-HPR–THU0594-HPR	Psychology/social sciences	1196

Friday, 13 June 2014

Guided Poster Tour

F3: HPR: Evaluating practice
(FRI0575-HPR, THU0584-HPR, THU0574-HPR, THU0592-HPR, THU0587-HPR, FRI0577-HPR, THU0580-HPR, FRI0578-HPR, THU0593-HPR)

Posters

FRI0561-HPR–FRI0591-HPR	Physiotherapy	1198
FRI0592-HPR–FRI0595-HPR	Occupational therapy	1209

Saturday, 14 June 2014

Guided Poster Tour

S2: HPR: Tracking the journey
(FRI0587-HPR, FRI0592-HPR, SAT0595-HPR, SAT0594-HPR, FRI0563-HPR, THU0591-HPR, THU0594-HPR, FRI0576-HPR, FRI0594-HPR)

Posters

SAT0589-HPR–SAT0595-HPR	Miscellaneous forms of clinical care	1210
-------------------------	--	------

Abstracts Accepted for Publication

AB1137-HPR–AB1151-HPR	Nursing	1214
AB1152-HPR–AB1162-HPR	Psychology/social sciences	1218
AB1163-HPR–AB1176-HPR	Physiotherapy	1222
AB1177-HPR–AB1179-HPR	Occupational therapy	1226
AB1180-HPR–AB1191-HPR	Miscellaneous forms of clinical care	1227

People with Arthritis and Rheumatism in Europe Abstracts

Oral Presentations

Wednesday, 11 June 2014

OP0021-PARE–OP0022-PARE	Political campaigning	1234
-------------------------	-----------------------------	------

Thursday, 12 June 2014

OP0121-PARE	I-Patient - the role of smart decision making	1234
OP0134-PARE	Don't let the economic crisis go to waste	1234

Friday, 13 June 2014

OP0243-PARE–OP0249-PARE	Abstract session: PARE	1235
OP0259-PARE	Healthy ageing I - growing up with an RMD	1237
OP0273-PARE	Healthy ageing II - growing older with an RMD	1238

Saturday, 14 June 2014

OP0288-PARE	Facilitating a normal life - easy travelling for people with RMDs	1238
OP0300-PARE–OP0301-PARE	Peer support in chronic diseases	1238

Poster Presentations

Guided Poster Tours

Thursday, 12 June 2014

PARE I
(PARE0001 to PARE0011)

Friday, 13 June 2014

PARE II
(PARE0012 to PARE0022)

Posters

Thursday, 12 June to Saturday, 14 June 2014

PARE0001	Building patient led organisations	1240
PARE0002–PARE0003	Best practice campaigning	1240
PARE0004–PARE0005	Patient information and education	1241
PARE0006	Innovations in arthritis health care	1241
PARE0007	Patient information and education	1242
PARE0008–PARE0009	Best practice campaigning	1242
PARE0010–PARE0011	Patient information and education	1243
PARE0012	Best practice campaigning	1243
PARE0013	Patient information and education	1244
PARE0014–PARE0015	Best practice campaigning	1244
PARE0016	Patient information and education	1244
PARE0017–PARE0018	Work and rehabilitation	1245
PARE0019	Best practice campaigning	1246
PARE0020	Patient information and education	1246
PARE0021	Psychosocial support	1246
PARE0022	Best practice campaigning	1247

Author Index	1249
---------------------------	------